Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of ...

Scientists have conducted breakthrough research that could lead to a universal cancer vaccine, revolutionizing how the ...

Inhibition of CCR5 by leronlimab induced PD-L1 expression on patient circulating tumor cells. Expression levels of CCR5 correlate with T cell infiltration in TNBC.

The SCG2 hormone allows tumors to suppress immune defenses, opening up a new therapeutic avenue against cancer.

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid ...

MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to ...

The immune checkpoint inhibitor combination regimen has become the initial standard of care for metastatic RCC, given its ...

We conducted a prospective study of patients with solid tumors who received pembrolizumab or atezolizumab at the National Institute of Oncology, Rabat from July 2018 to December 2023. We identified ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation and immunology (I&I), will present a ...

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders ...